NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free VYGR Stock Alerts $9.09 -0.19 (-2.05%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$9.08▼$9.3650-Day Range$7.15▼$9.6452-Week Range$6.06▼$14.34Volume764,070 shsAverage Volume839,784 shsMarket Capitalization$493.59 millionP/E Ratio2.94Dividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside76.0% Upside$16.00 Price TargetShort InterestHealthy4.16% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.32Based on 15 Articles This WeekInsider TradingSelling Shares$27,272 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.73) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.54 out of 5 starsMedical Sector103rd out of 946 stocksBiological Products, Except Diagnostic Industry11th out of 160 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Voyager Therapeutics has a forecasted upside of 76.0% from its current price of $9.09.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.16% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 5.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.4 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Voyager Therapeutics this week, compared to 5 articles on an average week.Search Interest18 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat FollowsOnly 51 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,272.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions58.81% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.73) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 2.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 2.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 172.14.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesMarch 19, 2024 | usatoday.comVoyager 1 is 15 billion miles from home and broken. Here's how NASA is trying to fix it.March 17, 2024 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 16, 2024 | msn.comNASA scientist viewed first Voyager images. What he saw gave him chills.March 15, 2024 | msn.comNASA's Voyager 1 Spacecraft made a little sense for the first time in monthsMarch 15, 2024 | usatoday.comNASA gave Voyager 1 a 'poke' amid communication woes. Here's why the response was encouraging.March 15, 2024 | msn.comNASA Is One Step Closer to Fixing Voyager 1March 15, 2024 | msn.comThe Voyager’s Golden Record: Real-Life Inspiration Behind Netflix’s The SignalMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 15, 2024 | forbes.comAiling Voyager 1 Spacecraft Offers Glimmer Of Hope To NASAMarch 14, 2024 | msn.comA cosmic ‘poke’ by NASA receives surprising response from Voyager 1March 14, 2024 | msn.comVoyager 1 starts making sense again after months of babbleMarch 14, 2024 | yahoo.comVoyager 1 Sputters Back to LifeMarch 14, 2024 | msn.comNASA finds clue while solving Voyager 1's communication breakdown caseMarch 14, 2024 | yahoo.comVoyager, Chandrayaan, Curiosity: How do spacecraft get their names?March 13, 2024 | seekingalpha.comVoyager Therapeutics: On Track To Deliver High Returns On InvestmentMarch 13, 2024 | finanznachrichten.deVoyager Therapeutics, Inc.: Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerMarch 13, 2024 | globenewswire.comVoyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerMarch 9, 2024 | americanbankingnews.comCitigroup Initiates Coverage on Voyager Therapeutics (NASDAQ:VYGR)March 9, 2024 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Upgraded by StockNews.com to BuyMarch 7, 2024 | realmoney.thestreet.comVoyager Therapeutics initiated with bullish view at Citi, here's whyMarch 4, 2024 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue ForecastsMarch 3, 2024 | ca.finance.yahoo.comVoyager Therapeutics Inc (VT6.BE)March 1, 2024 | markets.businessinsider.comVoyager Therapeutics Buy Rating Affirmed Amid Strong Pipeline and Financial HealthMarch 1, 2024 | benzinga.comVoyager Therapeutics: Q4 Earnings InsightsFebruary 29, 2024 | finanznachrichten.deVoyager Therapeutics, Inc.: Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsFebruary 29, 2024 | marketwatch.comVoyager Therapeutics Shares Rise 15% After 4Q Swing to ProfitSee More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$18.00 Low Stock Price Target$14.00 Potential Upside/Downside+76.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$3.09 Trailing P/E Ratio2.94 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins52.93% Pretax Margin53.49% Return on Equity63.89% Return on Assets40.79% Debt Debt-to-Equity RatioN/A Current Ratio4.96 Quick Ratio4.96 Sales & Book Value Annual Sales$250.01 million Price / Sales1.97 Cash Flow$2.96 per share Price / Cash Flow3.07 Book Value$5.37 per share Price / Book1.69Miscellaneous Outstanding Shares54,300,000Free Float51,749,000Market Cap$493.59 million OptionableOptionable Beta0.96 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $825.41kMr. Peter P. Pfreundschuh CPA (Age 55)Chief Financial Officer Comp: $172.73kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMs. Robin Swartz (Age 53)Chief Operating Officer Mr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Jacquelyn Fahey Sandell Esq.J.D., Chief Legal OfficerMs. Michelle Quinn SmithChief Human Resources OfficerMore ExecutivesKey CompetitorsValnevaNASDAQ:VALNAdaptive BiotechnologiesNASDAQ:ADPTReplimune GroupNASDAQ:REPLCaribou BiosciencesNASDAQ:CRBUMetagenomiNASDAQ:MGXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 47,711 shares on 3/11/2024Ownership: 4.659%Goldman Sachs Group Inc.Bought 38,906 shares on 3/1/2024Ownership: 0.409%Price T Rowe Associates Inc. MDSold 169,301 shares on 2/16/2024Ownership: 2.284%Vanguard Group Inc.Bought 47,711 shares on 2/15/2024Ownership: 5.751%Citadel Advisors LLCSold 8,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks. What is Voyager Therapeutics' stock price target for 2024? 5 equities research analysts have issued 12 month price objectives for Voyager Therapeutics' stock. Their VYGR share price targets range from $14.00 to $18.00. On average, they expect the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 76.0% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts. How have VYGR shares performed in 2024? Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR stock has increased by 7.7% and is now trading at $9.09. View the best growth stocks for 2024 here. When is Voyager Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VYGR earnings forecast. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $2 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%. What ETF holds Voyager Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.63%), Vanguard Group Inc. (5.75%), Vanguard Group Inc. (4.66%), Price T Rowe Associates Inc. MD (2.28%), Price T Rowe Associates Inc. MD (2.28%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYGR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBitcoin dollar warningStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.